Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Pediatric Brain Tumor 1Pancreatic Neoplasms 1Neoplasms 1Mesothelioma 1Melanoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1

Interventions

Pemetrexed 2Cisplatin 2talazoparib 1poly ICLC 1pembrolizumab 1milademetan 1atezolizumab 1Vorinostat 1Talc 1Surveys and Questionnaires 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Mesothelioma × poly ICLC × Clear all
NCT02661100 2016-12-07

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Case Comprehensive Cancer Center

Phase 1/2 Withdrawn
DermatologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡